Hologic's CFO provided a strategic overview at the Raymond James Institutional Investor Conference, emphasizing the company's focus on women's healthcare with market-leading products. Over 80% of the company's fiscal 2024 revenue was recurring, derived from disposables and services.
The Diagnostics division, Hologic's largest, has grown over 6% in the past decade, with molecular diagnostics expanding 2.5 times and Panther placements doubling to over 3,300 globally. The Biotheranostics acquisition, now approaching $125 million in revenue, is only 12% penetrated, indicating significant growth runway.
In Breast Health, the 3D Genius mammography system holds over 80% U.S. market share, with the next-generation Envision gantry expected in 2026. The Surgical division, which grew 7.6% over 10 years, was bolstered by the recent Gynesonics acquisition, enhancing its fibroid treatment portfolio. The company maintains strong operating margins in the low-30s and generates approximately $1 billion in annual cash flow.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.